TrianglePUBLICATIONS · 28441111
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2017 Jul 1
- First author
- Chen R
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Chen R
- type
- Author
- name
- Zinzani PL
- type
- Author
- name
- Fanale MA
- type
- Author
- name
- Armand P
- type
- Author
- name
- Johnson NA
- type
- Author
- name
- Brice P
- type
- Author
- name
- Radford J
- type
- Author
- name
- Ribrag V
- type
- Author
- name
- Molin D
- type
- Author
- name
- Vassilakopoulos TP
- type
- Author
- name
- Tomita A
- type
- Author
- name
- von Tresckow B
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Chen R
- type
- Author
- name
- Zinzani PL
- type
- Author
- name
- Fanale MA
- type
- Author
- name
- Armand P
- type
- Author
- name
- Johnson NA
- type
- Author
- name
- Brice P
- type
- Author
- name
- Radford J
- type
- Author
- name
- Ribrag V
- type
- Author
- name
- Molin D
- type
- Author
- name
- Vassilakopoulos TP
- type
- Author
- name
- Tomita A
- type
- Author
- name
- von Tresckow B
- type
- Author
- bibliography ids
- nci-bib-e50d2b2a8090d988f48c791d
- book metadata
- content sha256
- 2ec67cca8c4ea8ce207fae33f161832125400385c0a3a4b4668d35ab6941ad89
- document type
- citation
- dois
- 10.1200/JCO.2016.72.1316
- electronic publication date
- display
- 2017 Apr 25
- precision
- day
- year
- 2017
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:28441111
- immutable id
- pubmed:28441111@2ec67cca8c4ea8ce207fae33f161832125400385c0a3a4b4668d35ab6941ad89
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 19
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 2125-2132
- volume
- 35
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 28441111
- provenance
- batch id
- 1c173f0e18be0c6d461b
- provider
- NCBI PubMed ESummary
- record sha256
- eb48233ea2ff49e537c5c2d9e7c4b5d53bbd8cc7a32792e577b8e0c59d737b5a
- response sha256
- 27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
- retrieved at
- 2026-09-09T23:47:25.975513+00:00
- publication date
- display
- 2017 Jul 1
- precision
- day
- year
- 2017
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Preserved source evidence · Not medical advice